In vitro and in vivo studies of the Interferon-alpha action on distinct Orthobunyavirus.
Oropouche, Caraparu, Guama, Guaroa and Tacaiuma viruses (Orthobunyavirus genus) cause human febrile illnesses and/or encephalitis. To achieve a therapeutical agent to prevent and/or treat these diseases we evaluated the antiviral action of Interferon-alpha (IFN-alpha) on these orthobunyaviruses. In vitro results showed that all the studied orthobunyaviruses are susceptible to antiviral action of IFN-alpha, but this susceptibility is limited and dependent on both concentration of drug and treatment period. In vivo results demonstrated that IFN-alpha present antiviral action on Oropouche and Guaroa viruses when used as a prophylactic treatment. Moreover, a treatment initiated 3h after infection prevented the death of Guaroa virus infected-mice. Additionally, mortality of mice was related to the migration and replication of viruses in their brains. Our results suggest that IFN-alpha could be potentially useful in the prevention of diseases caused by Oropouche virus and in the prevention and/or treatment of diseases caused by Guaroa virus.
Livonesi
Márcia Cristina
MC
Center for Research in Virology, School of Medicine of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil. pink@rpm.fmrp.usp.br
de Sousa
Ricardo Luiz Moro
RL
Badra
Soraya Jabur
SJ
Figueiredo
Luiz Tadeu Moraes
LT
D000818:Animals; D000833:Animals, Suckling; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000821:virology; D002044:Bunyaviridae Infections / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D002522:Chlorocebus aethiops; D004305:Dose-Response Relationship, Drug; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D051379:Mice; D016851:Orthobunyavirus / Q000187:drug effects* / Q000254:growth & development; D011994:Recombinant Proteins; D015996:Survival Rate; D013997:Time Factors; D014709:Vero Cells; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins